Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 22;11(16):4922.
doi: 10.3390/jcm11164922.

Prognostic Factors of Survival in Patients with Peritoneal Metastasis from Colorectal Cancer

Fernando Mendoza-Moreno  1 , Manuel Diez-Alonso  1 , Belén Matías-García  1 , Enrique Ovejero-Merino  1 , Remedios Gómez-Sanz  1 , Alma Blázquez-Martín  1 , Ana Quiroga-Valcárcel  1 , Cristina Vera-Mansilla  1 , Raquel Molina  2 , Alberto San-Juan  2 , Silvestra Barrena-Blázquez  1 , Miguel A Ortega  3   4 , Melchor Alvarez-Mon  3   4   5 , Alberto Gutiérrez-Calvo  1
Affiliations

Prognostic Factors of Survival in Patients with Peritoneal Metastasis from Colorectal Cancer

Fernando Mendoza-Moreno et al. J Clin Med. .

Abstract

Objectives: The aim of this study was to analyze the prognostic factors of survival in patients with peritoneal metastasis (PM) from colorectal cancer (CRC). The type of relationship between survival and the PM time of detection was used to determine whether it was synchronous with the primary tumor or metachronous. Patients and Methods: Retrospective observational study. It included patients treated for colorectal adenocarcinoma diagnosed between January 2005 and December 2019 who presented PM at the time of diagnosis or during follow-up. Variables, such as sex, age, differentiation grade, positive adenopathy (pN+), tumor size (pT), tumor location, mucinous component, peritoneal carcinomatosis index (PCI), and KRAS mutational status, were analyzed. Results: During the study period, 1882 patients were surgically treated for CRC in our hospital. Of these, 240 patients (12.8%) were included in the study after evidence of PM. The mean age was 67 ± 12 years (range: 32−92 years), and 114 patients were female (47.5%). The mean follow-up was 20 ± 13 months (median 12 months). The Kaplan−Meier survival at 36 months was higher in patients with metachronous PM (24% vs. 8%; p = 0.002), WT-KRAS tumors (31% vs. 15%; p < 0.001), N0 stage (30% vs. 19%; p < 0.001), T3 stage tumors (18% vs. 19% in T4A and 3% in T4B; p > 0.001), and tumors with classic adenocarcinoma histology (18% vs. 8%; p = 0.011). Patients with a PCI of 1−10 showed a likelihood of survival at 36 months of 56%, which was longer than that found in patients with a PCI of 11−20 (8%) or a PCI of >20 (0%) (p < 0.001). In the multiple regression analysis, the factors with an independent prognostic value were: poor grade of differentiation (HR 1.995; 95% CI: 1.294−3.077), KRAS mutation (HR 1.751; 95% CI: 1.188−2.581), PCI 11−20 (HR: 9.935; 95% CI: 5.204−18.966) and PCI > 20 (HR: 4.011; 95% CI: 2.291−7.023). Conclusions: PCI should continue as the as the most useful prognostic indicator in order to assess prognostic estimations as well as therapeutic and surgical decisions, but tumor grade and KRAS mutational status may help in the treatment decision process by providing complementary information. The time of PM detection did not achieve statistical significance in the multiple regression analysis.

Keywords: colorectal cancer; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; metachronous peritoneal metastases; peritoneal carcinomatosis; peritoneal metastases; synchronous peritoneal metastases.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Kaplan-Meier survival function in the entire cohort according to the time of diagnosis of PM (Horizontal bar shows median survival).
Figure 2
Figure 2
Kaplan-Meier survival in the entire cohort according to KRAS mutation status (Horizontal bar shows median survival).
Figure 3
Figure 3
Kaplan-Meier survival curve according to PCI Index. Horizontal bar shows median survival.
Figure 4
Figure 4
Kaplan-Meier survival function curve according to PCI Index and KRAS mutation status (Horizontal bar shows median survival).
See this image and copyright information in PMC

References

    1. Xue L., Hyman N.H., Turaga K.K., Eng O.S. Peritoneal Metastases in Colorectal Cancer: Biology and Barriers. J. Gastrointest. Surg. 2020;24:720–727. doi: 10.1007/s11605-019-04441-4. - DOI - PubMed
    1. Lurvink R.J., Rijken A., Bakkers C., Lemmens V.E., de Reuver P.R., Tuynman J.B., Kok N.F., Nienhuijs S.W., van Erning F.N., de Hingh I.H.J.T. The impact of an open or laparoscopic approach on the development of metachronous peritoneal metastases after primary resection of colorectal cancer: Results from a population-based cohort study. Surg. Endosc. 2022 doi: 10.1007/s00464-022-09041-z. - DOI - PMC - PubMed
    1. Carlomagno C., De Stefano A., Rosanova M., De Falco S., Attademo L., Fiore G., De Placido S. Multiple treatment lines and prognosis in metastatic colorectal cancer patients. Cancer Metastasis Rev. 2019;38:307–313. doi: 10.1007/s10555-018-9748-7. - DOI - PubMed
    1. Sánchez-Hidalgo J.M., Rodríguez-Ortiz L., Arjona-Sánchez Á., Rufián-Peña S., Casado-Adam Á., Cosano-Álvarez A., Briceño-Delgado J. Colorectal peritoneal metastases: Optimal management review. World J. Gastroenterol. 2019;25:3484–3502. doi: 10.3748/wjg.v25.i27.3484. - DOI - PMC - PubMed
    1. Colloca G.A., Venturino A., Guarneri D. Different variables predict the outcome of patients with synchronous versus metachronous metastases of colorectal cancer. Clin. Transl. Oncol. 2020;22:1399–1406. doi: 10.1007/s12094-019-02277-7. - DOI - PubMed

LinkOut - more resources